2nd Fc Receptor & IgG Targeted Therapies Summit
Evvnt Promotion / evvnt
26.04.2022 - 28.04.2022 Hilton Boston Back Bay, 40 Dalton Street, 02115 Boston, USA
Time: 9:00 AM - 4:00 PM
Kongressthemen
FcRn, Fcγ, and IgG studies have been propelled by drug developers recently after Argenx’s potential FDA’s approval of first-in-class FcRn antagonist efgartigimod, AstraZeneca-Alexion’s $39 billion deal, and positive clinical updates from UCB’s Rozanolixizumab. Successful modulation of the Fc pathways and optimized IgG antibodies have proven clinical utility and demonstrate significant therapeutic potential with more players poised to bring their candidates through clinic.
FcRn, Fcγ, and IgG studies have been propelled by drug developers recently after Argenx’s potential FDA’s approval of first-in-class FcRn antagonist efgartigimod, AstraZeneca-Alexion’s $39 billion deal, and positive clinical updates from UCB’s Rozanolixizumab. Successful modulation of the Fc pathways and optimized IgG antibodies have proven clinical utility and demonstrate significant therapeutic potential with more players poised to bring their candidates through clinic.
Kongressorganizer (PCO)
Hanson Wade
Hanson Wade
Anfragen und Anmeldung:
https://go.evvnt.com/972245-1?pid=4832
Frau Erin Thomas
Allgemeinmedizin
Sprache
Englisch
Englisch
Kongressgebühr
Conference + 2 Workshops - Pharma Biotech USD 3897.00, Conference Only - Pharma Biotech USD 2999.00, Conference + 2 Workshops - Service provider USD 4697.00, Conference Only - Service provider USD 3599.00
Conference + 2 Workshops - Pharma Biotech USD 3897.00, Conference Only - Pharma Biotech USD 2999.00, Conference + 2 Workshops - Service provider USD 4697.00, Conference Only - Service provider USD 3599.00
Teilnehmer erwartet
1000
1000
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
83 Great Titchfield Street
W1W 6RH London
Großbritannien
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."
